Conatus Pharmaceuticals Inc (CNAT) was Resumed by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jul 1, 2016.
On the company’s financial health, Conatus Pharmaceuticals Inc reported $-0.35 EPS for the quarter, based on the information available during the earnings call on May 5, 2016. Analyst had a consensus estimate of $-0.35.During the same quarter in the previous year, the company posted $-0.38 EPS.
Conatus Pharmaceuticals Inc opened for trading at $2.03 and hit $2.24 on the upside on Wednesday, eventually ending the session at $2.16, with a gain of 6.40% or 0.13 points. The heightened volatility saw the trading volume jump to 1,01,728 shares. Company has a market cap of $46 M.
In a different news, on Apr 10, 2015, Daniel L Kisner (director) purchased 4,000 shares at $5.75 per share price.
Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company’s lead compound emricasan is an orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases which are enzymes that mediate inflammation and apoptosis. It is conducting a clinical program to demonstrate the therapeutic benefit of emricasan in patients with chronic liver disease across the spectrum of liver disease including liver cirrhosis (LC); liver cirrhosis with portal hypertension (PH); post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR) and non-alcoholic fatty liver disease (NAFLD) including patients with inflammatory and/or fibrotic non-alcoholic steatohepatitis (NASH).